ADVERTISEMENT AUGUST 2014 INTRODUCING SENSEI LABS THE LATEST INNOVATION FROM KLICK HEALTH BASED ON THE NY TIMES BESTSELLER THE DECODED COMPANY SENSEI LABS WORKS WITH BIOTECHS TO DEVELOP + COMMERCIALIZE FASTER SEE IT AT KLICK.COM/SENSEILABS magentablackcyanyellow ES468223_PE0814_CVTP1_FP.pgs 07.22.2014 19:50 ADV SENSEI LABS WORKS WITH BIOTECHS TO DEVELOPDEVELOP + + COMMERCIALIZER COMMERCIALIZE FASTERFASTER SENSEI LABS DEVELOPS TECHNOLOGIES TO ALIGN ORGANIZATIONS’ BELIEF SYSTEMS AND OPERATING SYSTEMS SO YOU CAN GET TO MARKET FASTER. WHETHER ESTABLISHING YOUR R&D ORGANIZATION AND INTERNAL PROCESSES, COMMUNICATING WITH INVESTIGATORS, OR PREPARING FOR COMMERCIALIZATION, EVERY MINUTE COUNTS. MOVE FASTER. READ THE CASE STUDY AT KLICK.COM/SENSEILABS magentablackcyanyellow ES468224_PE0814_CVTP2_FP.pgs 07.22.2014 19:50 ADV HEALTH REFORM EUROPEAN COMPETITIVENESS M&A CHECKLIST BREAK THE SILOS EFPIA’S BATTLE PLAN DOING DUE DILIGENCE AUGUST 2014 AUGUST 2014 WHERE BUSINESS MEETS POLICY VOLUME 34, NUMBER 8 WWW.PHARMEXEC.COM Emerging Pharma Leaders Health System Changes M&A Due Diligence European Innovation 2014 VOLUME 34, NUMBER 8 34, VOLUME Emerging Pharma Leaders magentablackcyanyellow ES475633_PE0814_cv1.pgs 07.30.2014 19:43 ADV Helping people takes people—13,000 to be exact—that can handle everything from the high-tech, worldwide distribution of specialty oncology therapies to spending time on the phone counseling a worried patient. It takes a global healthcare solutions leader dedicated to enhancing patient care through end-to-end solutions for manufacturers, pharmacies and providers. It takes AmerisourceBergen. ItTakesAmerisourceBergen.com magentablackcyanyellow ES469088_PE0814_CV2_FP.pgs 07.24.2014 00:07 ADV PHARMACEUTICAL EXECUTIVE AUGUST 2014 www.PharmExec.com From the Editor 3 Leader Speak PHARM EXEC’s 2014 rOSTER OF EMERGING LEADERS—our eighth, comprising an honor class of nearly 200 recipients to date—is more than just a way to recognize young execu- tives who’ve made a difference in their organizations. Each list also serves as a window on work in an industry that, perhaps more than any other, relies on human capital as the coinage of success. Because our nominees are selected on the basis of a track record in directing teams, we can identify current trend lines around leadership behaviors: in a distracted world, fxing clear goals, with messages that motivate; keeping people on point and accountable for results; taking on reasonable risks while accommodating failure; and avoiding those process regimens that plague large institutions through a commitment to William Looney diversity—in culture, ideas, and talent. Editor-in-Chief [email protected] he following is a capsule summary of in- There will be no profts from tomorrow’s individ- Follow Bill on Twitter: T sights about our changing industry gleaned ually targeted biologics if process technologies fail from the 15 emerging leader profles com- to keep pace with the complexities of reproducing @BillPharmExec piled by the Pharm Exec editorial staff: them in a scalable, cost-effcient manner, for safe New competitors in the pharma space. This use by patients worldwide. year’s list features two young CEOs from Russia Numbers don’t tell the full story. While and Portugal whose companies are venturing big data has been touted as the solution to the beyond their protected domestic base to test industry’s evidentiary challenges, there is a grow- big-time opportunities in the US, Europe, and ing awareness that numbers alone do not create Japan. Antonio Portela, CEO of Portugal’s Bial, the interpretive knowledge required to guide capped years of effort in securing an FDA market- decisions. A prized asset for managers these days ing license in November 2013 for the epileptic is the ability to draw insights, establish context, drug Aptiom—the frst new medicine developed and simplify the complex, which means that data in Portugal for sale in the US. R-Pharm CEO is best applied as a tool toward that larger end, Aleksey Repik is transforming Russia’s second- where the necessary judgments must be made by largest domestic drug company into a global people relying on learned experience and—yes — player linked to a network of partnerships with intuition. It follows that none of our leaders wish the cream of big Pharma, all while making his to be known as “quants,” but emphasize those company top of the league within Russia as the softer people skills that allow managers to adapt sole local producer able to meet global standards and stay ahead of the curve imposed by today’s for GMP. Both companies are family owned, a unruly markets. As one leader says, “always start familiar model for successful businesses in the with the end in mind.” And data can only take emerging market countries, and one that insulates you part of the way. them from the short-term investor pressures as- Science is shaping career choices. As the sociated with being publicly held. Interestingly, recording of the human genome allows more many of today’s big Pharma players started out precise targeting of drugs to address specifc the same way—give or take a century. conditions, all diseases are becoming rare diseases, Globalization of the talent pipeline. Job assign- with dozens of specialty biologics to treat them ments and career growth are tracking to a much now emerging from industry labs. For our leaders more global trajectory, with many of our leaders in commercial development, the best therapeutic remarking how they have benefted from postings opportunities are now found in this space. This outside their cultural comfort zones. Europeans is despite the fact they all cut their management are obtaining high-profle assignments managing teeth on traditional small-molecule products for US businesses, while one of our American lead- chronic, big population conditions applied in pri- ers became a change agent in transforming his mary care settings with a high level of generic pen- company’s approach to market analytics in Japan. etration. The transition to specialty drugs imposes Overall, the immigrant experience continues to a signifcant learning curve on all marketers, and enrich the managerial talent pool in the US. Leg- this generation of leaders is frst to experience it. islators in Washington, take note. silo thinking—the albatross that still wanders. supply chain manufacturing—from pumpkin to Organizational structure, offce politics, culture the gilded coach. As three of our leaders can at- barriers, and the inbreeding created by functional- test, operations management is no longer a techni- ized expertise remains the key obstacle to turning cal backwater but a front line strategic capability strategy into results. The will to change has to be that has the undivided attention of the “c-suite.” matched with real incentives, says our group. magentablackcyanyellow ES472822_PE0814_003.pgs 07.26.2014 04:05 ADV PHARMACEUTICAL EXECUTIVE AUGUST 2014 www.PharmExec.com 4 Pharmaceutical Executive’s 2014 Editorial Advisory Board is a distinguished group of thought leaders with expertise in various facets of pharmaceutical research, business, and mar- keting. EAB members suggest feature subjects relevant to the VOLUME 34, NUMBER 8 industry, review article manuscripts, participate in and help VP OF SALES & GROUP PUBLISHER TEL [732] 346.3018 Russ Pratt [email protected] sponsor events, and answer questions from staff as they arise. EDITOR-IN-CHIEF TEL [212] 951.6735 William Looney [email protected] Murray L. Aitken Clifford Kalb MANAGING EDITOR TEL [732] 346.3022 Senior Vice President, President, Michael Christel [email protected] Healthcare Insight, C. Kalb & Associates IMS Health SENIOR EDITOR TEL [212] 951.6738 Bernard Lachappelle Benjamin Comer [email protected] Stan Bernard President, EUROPEAN & ONLINE EDITOR TEL 011 44 [208] 956.2660 President, JBL Associates Julian Upton [email protected] Bernard Associates SPECIAL PROJECTS EDITOR TEL [212] 951.6742 Rajesh Nair Marylyn Donahue [email protected] Frederic Boucheseiche President, COMMUNITY MANAGER TEL [732] 346.3009 Chief Operating Off cer, Indegene Hannah Becker [email protected] Focus Reports Ltd. Daniel Pascheles ART DIRECTOR TEL [218] 740.6411 Joanna Breitstein Vice President, Steph Johnson-Bentz [email protected] Director, Communications, Global Business Intelligence, WASHINGTON CORRESPONDENT TEL [301] 656.4634 Global TB Alliance Merck & Co. Jill Wechsler [email protected] EDITORIAL OFFICES TEL [212] 951.6600 Drew Bustos Elys Roberts Vice President, Global Communications, President, 641 Lexington Avenue, 8th f oor FAX [212] 951.6604 Cegedim Relationship Management Ipsos Healthcare North America New York, NY 10022 www.pharmexec.com SALES MANAGER-EAST COAST TEL [732] 346.3054 Don Creighton Barbara Ryan Mike Moore [email protected] Managing Director, FTI Consulting Senior Director, Market Access, SALES MANAGER–MIDWEST, SOUTHWEST, WEST COAST TEL [847] 283.0129 PriceSpective, an ICON Company Alexander Scott Bill Campbell [email protected] SENIOR PRODUCTION MANAGER TEL [218] 740.6371 Rich Daly Vice President, Business Development, Karen Lenzen [email protected] President, Eisai Corp. of North America AstraZeneca Diabetes AUDIENCE DEVELOPMENT MANAGER TEL [218] 740.7285 Michael Swanick Kelly Kemper [email protected] Global Practice Leader Pharmaceuticals Rob Dhoble REPRINTS 877-652-5295 EXT. 121 and Life Sciences, PwC CEO, [email protected] Adherent Health Mason Tenaglia Outside US, UK, direct dial: